Denali Therapeutics
DNLI
170 hedge funds and large institutions have $2.96B invested in Denali Therapeutics in 2020 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 54 increasing their positions, 48 reducing their positions, and 20 closing their positions.
110% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 20
48% more capital invested
Capital invested by funds: $2B → $2.96B (+$960M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
15% more funds holding
Funds holding: 148 → 170 (+22)
13% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 48
0.26% less ownership
Funds ownership: 78.36% → 78.09% (-0.26%)
18% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $2.55M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$52.4M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$46.6M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$10.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$8.63M |
| 5 |
Goldman Sachs
New York
|
+$8.36M |
Top Sellers
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$60.2M |
| 2 |
CM
Crestline Management
Fort Worth,
Texas
|
-$43.5M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$17.7M |
| 4 |
CCM
CAAS Capital Management
New York
|
-$15M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$11.9M |
DNLI Hedge Fund Activity: Q3 2020 in Review
170 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2020, worth a combined $2.96B — up 48% from $2B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new DNLI positions and 20 closed out — a net gain of 22 holders — while 54 added to existing stakes and 48 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $52.4M. The largest seller was Flagship Pioneering, cutting an estimated $60.2M.
- 170 institutional investors held Denali Therapeutics (DNLI) as of Q3 2020, up from 148 in Q2 2020.
- Funds reported $2.96B of Denali Therapeutics stock for Q3 2020, up 48% quarter-over-quarter.
- 42 funds opened new Denali Therapeutics positions in Q3 2020 and 20 closed out, a net change of +22 holders.
- The largest Denali Therapeutics buyer in Q3 2020 was T. Rowe Price Associates, an estimated $52.4M added.
- The largest Denali Therapeutics seller in Q3 2020 was Flagship Pioneering, an estimated $60.2M sold.
Based on aggregated 13F filings for Q3 2020.